Enrollment underway in second Avacta clinical program at first three specialist U.S. oncology centers Initial data from the trial expected later this year LONDON and PHILADELPHIA, March 31, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, is pleased to announce today, that the first patient has been treated in the FOCUS-01 trial, the multicenter, open-label Phase ...

LONDON and PHILADELPHIA, March 17, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, "the Company", "Avacta"), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced it will deliver two presentations at the American Association for Cancer Research (AACR) Annual Meeting 2026, taking place from 17 April 2026 to 22 April 2026 in San Diego, California, USA. Details of the two presentations: Title: AVA6103 is a FAP-enabled pre|CISIO ...

Core Viewpoint - Avacta Therapeutics has demonstrated that its proprietary pre|CISION platform offers significant advantages over the marketed antibody drug conjugate (ADC) Enhertu, with plans to initiate a clinical trial for FAP-Exd (AVA6103) in Q1 2026 [1][3]. Group 1: Clinical Data and Comparisons - The analysis compares the delivery profile of pre|CISION FAP-cleavable payload with Enhertu, which is approved for breast and gastric cancer [3]. - The pre|CISION platform shows three key advantages: faster drug penetration into tumors, a higher maximum drug concentration in tumors, and a nearly three-fold higher Tumor Selectivity Index compared to Enhertu [4][9]. - The maximum concentration (Cmax) of FAP-Exd in tumor tissue occurs within minutes, while T-Dxd reaches its maximum concentration at 24 hours [9]. Group 2: Mechanism and Efficacy - The pre|CISION delivery mechanism is designed to selectively deliver potent payloads to tumors while minimizing exposure to normal tissues, enhancing safety and effectiveness [11][13]. - The analysis indicates that FAP-Exd shows higher activity in tumor models with low FAP expression compared to T-Dxd's variable activity at low HER2 expression levels [7]. - Deep and durable responses were observed with FAP-Exd, persisting for weeks after a three-dose regimen [7]. Group 3: Future Plans and Innovations - Avacta plans to present these findings at an upcoming scientific congress and submit them to a peer-reviewed journal [8]. - The use of AI to create a synthetic comparator arm for data analysis highlights the innovative approach of the company's research team [5][6].

Core Viewpoint - Avacta Therapeutics has appointed Francis Wilson as Chief Scientific Officer, recognizing his significant contributions to the development of the pre|CISION oncology delivery platform and his leadership in medicinal chemistry [1][5]. Company Leadership - Francis Wilson joined Avacta in September 2022 as Vice President of Chemistry and has been pivotal in advancing the pre|CISION platform, particularly the FAP-Exd (AVA6103) program, which is expected to enter clinical testing soon [2][4]. - Former CSO Michelle Morrow will be leaving the company to pursue other opportunities, and the company expresses gratitude for her contributions [4]. Expertise and Background - Francis Wilson has extensive experience in medicinal chemistry, having held various positions at Roche, Xenova, Cellzome, and Summit Therapeutics, where he led multiple programs from discovery to clinical development [3]. - He holds a chemistry degree and a Doctor of Philosophy from Oxford University, and is a Chartered Chemist and Fellow of the Royal Society of Chemistry [4]. Strategic Direction - CEO Christina Coughlin emphasized Wilson's deep knowledge of the pre|CISION platform and his ability to foster innovation, which will be crucial as the company enters a significant phase of preclinical development and intellectual property generation [5]. - Wilson expressed enthusiasm for his new role and the opportunity to advance the AVA6103 program, highlighting the importance of developing novel intellectual property around the pre|CISION platform [6]. Technology Overview - The pre|CISION platform is a proprietary tumor-activated delivery system designed to concentrate potent cancer therapies in the tumor microenvironment while minimizing exposure to healthy tissues [9][11]. - It utilizes a tumor-specific protease (fibroblast activation protein or FAP) to release active payloads in the tumor, optimizing dosing and reducing systemic toxicity [11].

Cardiac dosing limit removed and path forward to dose selection identifiedLONDON and PHILADELPHIA, Feb. 03, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT, “the Company”, “Avacta”), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published two key clinical updates to its faridoxorubicin (AVA6000) clinical program. Agreed updates to the trial protocol include the removal of the maximum dosing limit and to allow flexibility in dosin ...

Core Insights - Avacta Therapeutics has received FDA clearance for the Investigational New Drug (IND) application for FAP-Exd (AVA6103), marking a significant step in the development of this oncology drug [1][2] - The Phase 1 clinical trial will assess the safety and efficacy of FAP-Exd in patients with pancreatic cancer, cervical cancer, gastric cancer, and small cell lung cancer, utilizing an AI approach to select these tumor types [2][3] - The trial will include adult participants in a dose-escalation study with two administration schedules, with preliminary data expected in the second half of 2026 [3] Company Developments - The transition of FAP-Exd from lab to human testing within 24 months demonstrates the company's efficiency in advancing its programs [3] - The innovative sustained release mechanism of FAP-Exd aims to enhance efficacy while minimizing toxicities associated with exatecan [3] - The clinical program is expected to provide insights into the pre|CISION platform's chemistry and validate the potential for varied payloads based on novel technologies [3] Technology Overview - The pre|CISION platform is designed to deliver potent cancer therapies by concentrating them in the tumor microenvironment while sparing normal tissues [5][7] - The platform utilizes a proprietary peptide that targets fibroblast activation protein (FAP), which is upregulated in most solid tumors, allowing for optimized dosing and reduced systemic toxicity [6][7]

LONDON and PHILADELPHIA, Jan. 20, 2026 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, has published a trading update for the year ended December 31, 2025. The Company made excellent progress during 2025, developing its unique industry-leading technology platform, pre|CISION®, with two programs anticipated to be in clinical development in 2026. The Company raised £22.5m in equity during 2025 ...

Core Viewpoint - Avacta Group Plc is presenting data on faridoxorubicin in Phase Ib trials for patients with salivary gland cancers, highlighting the innovative pre|CISION drug delivery system that enhances treatment efficacy while minimizing toxicity [2][3]. Group 1: Drug Delivery System - The pre|CISION program utilizes a FAP-activated drug delivery mechanism that allows a toxic drug to remain inactive in the bloodstream and normal tissues, becoming active only at the tumor site [3]. - The mechanism involves the binding of a pre|CISION peptide that masks the toxic payload, with drug release triggered by fibroblast activation protein (FAP) found in tumor-supporting cells [3]. Group 2: Treatment Benefits - This targeted approach reduces exposure of normal tissues and bone marrow to toxic effects, enabling prolonged treatment durations compared to conventional therapies [4]. - Enhanced survival rates have been observed due to the ability to administer treatment beyond the limits of traditional oncology drugs [4].

Preliminary Phase 1b data is in line with Phase 1a data reported at the European Society of Medical Oncology in September 2025 Combined disease control rate of 90% across both Phase 1a and Phase 1b patients with confirmed partial and minor responses observed LONDON and PHILADELPHIA, Dec. 17, 2025 (GLOBE NEWSWIRE) -- Avacta Therapeutics (AIM: AVCT), a clinical stage biopharmaceutical company developing pre|CISION®, a tumor-activated oncology delivery platform, today announced compelling new data in patients ...

Core Insights - Avacta Therapeutics has presented preclinical data on its first-in-class dual payload peptide drug conjugate, AVA6207, which aims to enhance tumor control and overcome resistance mechanisms in cancer therapy [1][2]. Company Overview - Avacta is a clinical stage biopharmaceutical company focused on developing the pre|CISION platform, which enables targeted delivery of oncology drugs through peptide drug conjugates (PDCs) [13]. Technology and Innovation - The dual payload technology allows for the simultaneous delivery of two distinct therapeutic agents to the tumor microenvironment via a single fibroblast activation protein (FAP)-mediated cleavage event, addressing critical challenges in cancer treatment [2][3]. - The pre|CISION platform has demonstrated a tumor-to-plasma payload concentration of 100:1 with reduced off-target toxicities, even at doses up to approximately four times that of conventional doxorubicin [5]. Preclinical Findings - The dual payload technology showed robust FAP-selective delivery and potent anti-tumor activity, with IC50 values ranging from 2-9 nM in the presence of FAP, indicating excellent tumor selectivity [6]. - The technology confirmed dual mechanism biomarker modulation, with specific biomarkers being affected only in the presence of FAP, validating the effectiveness of the dual payload approach [6][7]. - Enhanced synergistic activity was observed, with FAP-dependent tumor cell killing being 4-5 times greater compared to exatecan alone, effectively addressing known resistance pathways [7]. Market Potential - The pre|CISION platform targets a large addressable market, potentially impacting 90% of solid tumors, and offers advantages over traditional antibody drug conjugates (ADCs) such as better tumor penetration and reduced toxicity [7].